Revenue
2019
2020
2021
2022
2023
2024
2025
Treace Medical Concepts, Inc. (TMCI)
Price$4.81Cached quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $212.7M | $209.4M | $187.1M | $141.8M | $94.4M | $57.4M | $39.4M |
| Gross profit | $169.8M | $168.3M | $151.9M | $116.3M | $77.5M | $44.9M | $31.8M |
| Gross margin | 79.81% | 80.37% | 81.20% | 82.00% | 82.11% | 78.26% | 80.64% |
| Research & development | $20.3M | $20.6M | $15.4M | $13.6M | $10.2M | $5.8M | $5.1M |
| Operating expenses | $223.9M | $224.0M | $203.4M | $151.2M | $94.0M | $44.0M | $35.3M |
| Operating income | −$54.2M | −$55.7M | −$51.4M | −$34.8M | −$16.5M | $855,000 | −$3.5M |
| Operating margin | −25.46% | −26.60% | −27.48% | −24.57% | −17.49% | 1.49% | −8.97% |
| EBITDA | −$43.5M | −$47.3M | −$46.1M | −$32.7M | −$15.8M | $2.1M | −$2.7M |
| EBITDA margin | −20.47% | −22.58% | −24.62% | −23.06% | −16.76% | 3.60% | −6.96% |
| Net income | −$59.0M | −$55.7M | −$49.5M | −$42.8M | −$20.6M | −$3.7M | −$4.3M |
| Net profit margin | −27.74% | −26.63% | −26.47% | −30.19% | −21.77% | −6.39% | −10.82% |
| Basic EPSper basic share | -$0.93 | -$0.90 | -$0.81 | -$0.77 | -$0.43 | -$0.12 | -$0.13 |
| Diluted EPSper diluted share | -$0.93 | -$0.90 | -$0.81 | -$0.77 | -$0.43 | -$0.12 | -$0.13 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Treace John T. | 12.67M |
TREACE JAMES T | 1.78M |
MOTT RICHARD W | 1.1M |
Hair Mark | 952K |
Elder Scot Michael | 794.94K |
Scanlan Sean F. | 704.68K |
Guglielmino Gaetano | 490.9K |
BAKEWELL JOHN K | 296.36K |
Berutti Aaron | 205.09K |
Jain Deepti | 100.24K |
Kiernan Jane E | 93.95K |
Hanna Betsy | 75.24K |
Berry Lance A | 74.59K |
HAMILTON LAWRENCE W | 74.06K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 4/A ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 11, 2026Form 4/A | Treace John T.Chief Executive Officer | BuyCommon Stock | 9.9K | $4.04 | $40.0K | 7.35M |
| Jun 11, 2026Form 4 | Treace John T.Chief Executive Officer | BuyCommon Stock | 22.9K | $4.04 | $92.5K | 7.38M |
| Jun 10, 2026Form 4/A | Treace John T.Chief Executive Officer | BuyCommon Stock | 14.7K | $4.02 | $59.2K | 7.34M |
| Jun 10, 2026Form 4 | Treace John T.Chief Executive Officer | BuyCommon Stock | 29.4K | $4.02 | $118.3K | 7.35M |
| Jun 1, 2026Form 4 | Treace John T.Chief Executive Officer | BuyCommon Stock | 50.0K | $3.56 | $178.0K | 7.32M |